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Involvement of the Renin–Angiotensin System in the
Development of Vascular Damage in a Rat Model of Arthritis
Effect of Angiotensin Receptor Blockers
Takeo Sakuta,1 Yoshitaka Morita,1 Minoru Satoh,1 David A. Fox,2 and Naoki Kashihara1
Objective. To explore the involvement of the
renin–angiotensin system (RAS) in the development of
vascular damage in adjuvant-induced arthritis (AIA) in
rats.
Methods. Angiotensin II (Ang II; 0.25 or 1.0
mg/kg/day) was infused in control rats and rats with
AIA for 21 days, and the impact of systemic inflamma-
tion on Ang II–induced hypertension, endothelial dys-
function, and vascular hypertrophy was evaluated. Ex-
pression of angiotensin II type 1 receptor (AT1R) and
angiotensin-converting enzyme (ACE) in the aortas of
rats with AIA were examined by real-time polymerase
chain reaction (PCR) and Western blot analyses. Losar-
tan (3 mg/kg/day) or irbesartan (5 mg/kg/day), both of
which are AT1R blockers, was administered orally to
rats with AIA for 21 days. In situ superoxide production
in aortas was assessed according to the fluorogenic
oxidation of dihydroethidium to ethidium. The expres-
sion and activity of NAD(P)H oxidases in aortas were
examined by real-time PCR analysis and lucigenin
chemiluminescence assay. Endothelial function in rats
with AIA treated in vivo or ex vivo with AT1R blockers
was also determined.
Results. The Ang II–induced hypertensive re-
sponse, endothelial dysfunction, and vascular hypertro-
phy were exacerbated in rats with AIA. Expression of
AT1R and ACE was increased in the aortas of rats with
AIA. Both losartan and irbesartan decreased the levels
of superoxide and the expression and activity NAD(P)H
oxidases in the aortas of rats with AIA. The endothelial
dysfunction in AIA was improved by the in vivo or ex
vivo treatment with AT1R blockers.
Conclusion. The locally activated RAS is involved
in the increased vascular oxidative stress and endothe-
lial dysfunction in AIA. Our findings have important
implications for clinical approaches to the reduction of
cardiovascular risk in patients with rheumatoid arthri-
tis.
The risks of cardiovascular disease and death are
higher among patients with rheumatoid arthritis (RA)
than among the general population (1–5). RA patients
have a marked increase in carotid atherosclerosis that is
independent of the classic risk factors (6). Recent stud-
ies have shown that the prevalence of cardiovascular
disease and preclinical atherosclerosis in RA is in-
creased to an extent that is at least comparable to that of
diabetes mellitus (7,8). It has been postulated that
systemic inflammation plays an important role in the
pathogenesis of cardiovascular disease in RA (9–11).
Endothelial cell injury is an early step in the
process of atherosclerosis. Previous studies identified
the presence of endothelial dysfunction in RA patients
with high levels of inflammatory activity (12–15). Con-
sistent with the findings in human studies, we have
shown impaired endothelial function in rats with
adjuvant-induced arthritis (AIA), a well-known animal
model of RA (16,17). Reactive oxygen species, which
likely contribute to the pathophysiology of endothelial
dysfunction, were shown to be overproduced in the aorta
of rats with AIA (16). NAD(P)H oxidases are major
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sources of reactive oxygen species in the vasculature
(18), and these enzymes were found to be responsible
for the vascular oxidative stress in AIA (16,17). We
postulated that further studies using the same model
would provide additional understanding of the patho-
physiology of vasculopathies in systemic inflammatory
diseases.
It has been well established that activation of the
renin–angiotensin system (RAS) plays an important role
in the physiology and pathophysiology of the cardiovas-
cular system. Angiotensin II (Ang II) regulates blood
pressure and electrolyte homeostasis and contributes to
the inflammatory response in the vascular wall (19). Ang
II enhances the formation of cardiac and vascular reac-
tive oxygen species through stimulation of NAD(P)H
oxidase (20–22), causing endothelial dysfunction. In-
deed, it has been demonstrated that RAS blockers, such
as angiotensin-converting enzyme (ACE) inhibitors and
angiotensin II type 1 receptor (AT1R) blockers, improve
endothelial dysfunction in animal models and in patients
with various vascular disease states, such as hypercho-
lesterolemia and diabetes mellitus (23–25). Such agents,
moreover, reduce both cardiovascular morbidity and
mortality in these patients (26,27). These findings indi-
cate the critical involvement of the RAS in the develop-
ment of vascular damage caused by classic risk factors.
A role of the RAS in the pathophysiology of
vasculopathies in RA or systemic inflammatory diseases
has yet to be clearly established. Eight weeks of treat-
ment with quinapril, an ACE inhibitor, in patients with
RA was shown to have no significant effects on the
endothelial vascular responses (28). However, treatment
with ramipril, another ACE inhibitor, was found to
improve the endothelial dysfunction in RA patients
without affecting systemic inflammation (29). No data
have previously been reported that explore the role of
the RAS in the development of vascular damage in
animal models of systemic inflammation, and data on
the effects of AT1R blockers are also needed. Thus, we
set out to determine whether RAS activation is involved
in early vascular damage in the rat AIA animal model of
RA.
MATERIALS AND METHODS
Induction and treatment of AIA in rats. Six-week-old
male Lewis rats were obtained from Japan SLC. Complete
adjuvant was prepared by suspending heat-killed Mycobacte-
rium butyricum (Difco) in mineral oil at a concentration of 10
mg/ml. Rats were injected intradermally with 100 l of the
adjuvant at the base of the tail. The animals developed arthritis
10 days later. The normal nonarthritic and the arthritic rats
were divided into 3 treatment groups (5–6 rats per group): the
control group received saline infusion, the Ang II low group
received 0.25 mg/kg/day of Ang II, and Ang II high group
received 1.0 mg/kg/day of Ang II. Briefly, the rats were
anesthetized, and an osmotic pump containing 200 l of either
saline or Ang II (Sigma-Aldrich) was implanted subcutane-
ously. Ang II was administered at a dosage of 0.25 mg/kg/day
or 1.0 mg/kg/day for 21 days after the onset of arthritis.
Systolic arterial blood pressure was measured with a
tail-cuff system using a pulse transducer (BP98-A; Softron).
Rats were monitored for signs of arthritis, and the posterior
limbs were individually scored (0–3 scale). Scores were as-
signed based on the extent of erythema or swelling or the
severity of joint rigidity present in each posterior limb (maxi-
mum score of 6 per rat). Paw volume was measured with a
water-displacement plethysmometer (MK-101CMP; Muroma-
chi). Twenty-one days after the onset of arthritis, the rats were
killed, and the thoracic aortas were isolated for further exper-
iments.
In a separate experiment, 6-week-old male Lewis rats
(n  24) were divided into 4 groups (6 rats per group): a
normal control group, an AIA group, an AIA group treated
with losartan, and an AIA group treated with irbesartan. Rats
with AIA were administered 3 mg/kg of losartan (Sigma-
Aldrich) or 5 mg/kg of irbesartan (Dainippon Sumitomo
Pharma) by gavage once daily for 21 days after the onset of
arthritis.
All procedures were performed in accordance with our
institutional guidelines for animal research and were approved
by the Animal Care and Use Committee of Kawasaki Medical
School (no. 07-011).
Endothelium-dependent vascular responses in rats
with AIA. The aorta was dissected out and cut into 3.0-mm
rings, which were then placed in an organ bath. Endothelial
vascular function was evaluated as described previously (16).
Briefly, the aortic rings were suspended under 1g of tension
and were preconstricted by adding 3  10–7M norepinephrine.
After the contraction force had reached a plateau, acetylcho-
line (10–9–10–5M; an endothelium-dependent vasodilator) or
sodium nitroprusside (10–9–10–5M; an endothelium-
independent vasodilator) was added incrementally to the bath.
In some experiments, the rings were exposed to NG-nitro-L-
arginine methyl ester (L-NAME) (10–4M; a nitric oxide syn-
thase inhibitor) for 30 minutes before incubation with acetyl-
choline. The force of isometric contraction was measured using
a force-displacement transducer (model MTOB-1Z; Labo Sup-
port). Responses to acetylcholine were expressed as a percent-
age of the precontracted tension induced by norepinephrine.
Assessment of vascular wall hypertrophy. The thoracic
aorta was embedded in paraffin, and 4-m cross-sections were
cut starting 5 mm from the aortic arch. Sections were stained
with hematoxylin and eosin. To quantify wall thickness, the
distance from the internal elastic lamina to the external lamina
and the lumen diameter were measured at a minimum of 4
locations in the aortic section, and the ratio of the average
medial thickness to the lumen diameter was calculated. We
also evaluated the cross-sectional wall area. The perimeters of
the internal and external laminas were traced, and the area
inside each respective perimeter was determined. The lumen
area represented the area enclosed by the internal elastic
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lamina. The media area was obtained by subtracting the lumen
area from the area encompassed by the external elastic lamina,
and the ratio of media area to the lumen area was calculated.
All measurements were performed using National Institutes of
Health Image software (online at: http://rsb.info.nih.gov/nih-
image/).
Real-time quantitative polymerase chain reaction
(PCR) analysis. Total RNA was extracted with TRIzol reagent
using the single-step method. Reverse transcriptase reactions
were performed using a Ready-to-Go T-Primed First-Strand
kit (Amersham Biosciences) for synthesis of the first-strand
complementary DNA (cDNA). Real-time quantitative PCR
was performed using an ABI Prism 7700 sequence detection
system (Applied Biosystems). The sequences of primers and
probes used for NAD(P)H oxidase components (p22phox and
gp91phox), AT1R, and ACE have been described previously
(30–32). The cDNA from serially diluted samples was ampli-
fied using Premix Ex Taq (Takara Bio). The threshold cycle is
the PCR cycle at which an increase in the fluorescent emission
above the baseline signal is first detected. Since the value of
the threshold cycle decreases proportionally with increased
target quantity, it was used to determine the relative amount of
cDNA in each sample and to evaluate the levels of p22phox,
gp91phox, AT1R, and ACE messenger RNA (mRNA), which
were normalized to the quantity of GAPDH mRNA, as
described previously (17,33).
Western immunoblotting. The expression of AT1R in
aortas isolated from rats was assessed by Western blotting in
the same manner as described previously (16,17). Anti-AT1R
antibody (Abcam) and anti-GAPDH antibody (Santa Cruz
Biotechnology) were used as the primary antibodies.
Determination of ACE activity. Aortic ACE activity
was measured in a fluorescence assay using a commercial ACE
activity assay kit (Life Laboratory). Briefly, samples of aorta
were homogenized in an assay buffer and then clarified by
centrifugation at 8,000g for 10 minutes at 4°C. ACE activity
against a synthetic substrate (benzyloxycarbonyl-phenyl-alanyl-
leucine) was determined using a colorimetric method. The
product was measured fluorometrically at 320 nm of excitation
and 405 nm of emission with a fluorocolorimeter, and the
results were expressed relative to the control values in normal
rats. All measurements were performed in duplicate.
In situ measurement of superoxide (O2
) by confocal
fluorescence microscopy. The oxidative fluorescent indicator
dihydroethidium was used to evaluate in situ O2
 generation,
as described previously (17). Briefly, fresh aortic rings embed-
ded in OCT compound were cut into 20-m–thick sections,
submerged in 2 M dihydroethidium (Sigma-Aldrich) in phos-
phate buffered saline (PBS), and incubated at 37°C for 30
minutes. At the end of this incubation period, the slides were
washed with PBS and maintained at 4°C. Fluorescence was
detected with a 585-nm long-pass filter by using a laser
scanning confocal microscope (Leica Microsystems). The
mean fluorescence intensity of aortic tissues (total of 24
locations in the aortic section from 6 rats per group) was
analyzed with Leica TCS-NT system software (Leica Microsys-
tems), and the results were expressed relative to the control
values in normal rats.
Measurement of NAD(P)H oxidase activity. NAD(P)H
oxidase activity in isolated aortas was assessed by lucigenin
chemiluminescence after addition of NADPH in the same
manner as described previously (22). Briefly, 100 g of protein
from aortic samples was diluted in modified HEPES buffer
(140 mM NaCl, 5 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 1
mM Na2HPO4, 25 mM HEPES, and 1% glucose, pH 7.2).
Dark-adapted lucigenin (5 M), with or without NADPH (100
M), was added just before reading. Lucigenin chemilumines-
cence was recorded for 3 minutes and was expressed as units
per minute per milligram of weight (unit/minute/mg).
Measurement of serum levels of tumor necrosis factor
 (TNF). Serum samples were collected 21 days after arthritis
onset from rats with AIA treated or not treated with Ang II as
well as from control rats. Serum concentrations of rat TNF
were determined by enzyme-linked immunosorbent assay
(ELISA) using paired antibodies (R&D Systems) according to
the manufacturer’s instructions. The lower limit of detection
for this cytokine was 62.5 pg/ml.
Ex vivo treatment of aortas from rats with AIA with
AT1R blockers. The aortic rings isolated from rats with AIA
were resuspended in RPMI 1640 (Life Technologies) supple-
mented with 1% heat-inactivated fetal calf serum. After incu-
bating the aortas for 18 hours with or without 10 M losartan
or irbesartan in 96-well flat-bottomed plates, the endothelium-
dependent vascular responses were determined as described
above.
Statistical analysis. Data are expressed as the mean 
SEM of the indicated number of samples studied. The Mann-
Whitney U test was used to compare group data. P values less
than 0.05 were considered statistically significant.
RESULTS
Exacerbation of Ang II–induced vascular re-
sponses in rats with AIA. Treatment with Ang II induces
hypertension, endothelial dysfunction, and vascular hy-
pertrophy in animals (21,34). We first examined whether
systemic inflammation in AIA affects Ang II–induced
vascular responses in rats. Normal control rats and rats
with AIA were treated with saline or exogenous Ang II
at a dosage of 0.25 or 1.0 mg/kg/day for 21 days. The
severity of clinical arthritis was not affected by Ang II
infusion during the course of disease (results not
shown). Of note, the hypertensive response to Ang II
was more profound (P  0.05) in rats with AIA than in
nonarthritic rats (Figure 1A).
We next evaluated endothelium-dependent vaso-
dilatory responses in rats with AIA treated with saline or
Ang II (Figure 1B). Ang II resulted in a dose-dependent
and significant depression of endothelium-dependent
vasodilation. We found that the Ang II–induced endo-
thelial dysfunction was significantly exacerbated (P 
0.05) in rats with AIA as compared with that in nonar-
thritic rats.
To evaluate vascular hypertrophy, we also exam-
ined the medial thickness of aortas from rats with AIA
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treated with saline or Ang II (Figure 2). The medial
thickness was slightly, but significantly (P  0.05),
greater in saline-infused rats with AIA than in normal
control rats. Treatment with Ang II resulted in dose-
dependent and significant increases in medial thickness
(P  0.05) but not lumen diameter. These effects were
more profound (P  0.05) in rats with AIA than in
nonarthritic control rats. Similar results were obtained
when we evaluated the ratio of the medial thickness to
the lumen diameter and when we evaluated the cross-
sectional wall area. These results indicate that the Ang
II–induced vascular hypertrophic responses in rats were
significantly exacerbated in the presence of systemic
inflammation.
In the aortas of rats with AIA, oxidative stress is
increased, and NAD(P)H oxidases are responsible for
the vascular overproduction of O2
 (16,17). In the
present study, we found that mRNA expression and
activity of NAD(P)H oxidases in rat aortas were in-
creased by the induction of AIA as well as by the
infusion of Ang II infusion, and the increase was further
enhanced by the combination of both stimuli (results not
shown).
Serum concentrations of lipids were measured 21
days after the onset of arthritis. There was no difference
Figure 2. Aortic hypertrophy in rats with adjuvant-induced arthritis
(AIA) infused with angiotensin II (Ang II; low-dose 0.25 mg/kg/day or
high-dose 1.0 mg/kg/day). A, Representative images of hematoxylin
and eosin–stained aortic cross-sections (original magnification  200).
B, Aortic hypertrophy in nonarthritic rats (open bars) and rats with
AIA (solid bars), as indicated by the aortic medial thickness, the lumen
diameter, the ratio of the medial thickness (MT) to the lumen
diameter (LD), and the ratio of the media area to the lumen area. See
Materials and Methods for details. Values are the mean and SEM of
5–6 rats per group.   P  0.05 versus aortas from saline-infused
normal control rats; #  P  0.05 versus aortas from rats without
arthritis infused with low-dose Ang II; †  P  0.05 versus aortas from
rats without arthritis infused with high-dose Ang II.
Figure 1. Exacerbation of angiotensin II (Ang II)–induced hyperten-
sion and endothelial dysfunction in rats with adjuvant-induced arthritis
(AIA). Saline or Ang II (low-dose 0.25 mg/kg/day or high-dose 1.0
mg/kg/day) was administered to control rats and rats with AIA for 21
days after the onset of arthritis. A, Systolic blood pressure values
obtained on the indicated days. B, Endothelium-dependent vasodila-
tion induced by acetylcholine. Values are the mean  SEM of 5–6 rats
per group.   P  0.05 versus saline-infused normal control rats; # 
P  0.05 versus low-dose Ang II–infused rats without arthritis; †  P 
0.05 versus high-dose Ang II–infused rats without arthritis.
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between normal rats, untreated rats with AIA, and Ang
II–treated rats with AIA in terms of serum levels of total
cholesterol (mean  SEM 83.5  1.9 pg/ml in normal
rats, 68.7  0.5 in untreated rats with AIA, 83.0  2.6 in
rats treated with low-dose Ang II, 69.5  0.7 in rats with
AIA that received low-dose Ang II, 90.7  3.3 in rats
treated with high-dose Ang II, and 99.8  6.0 in rats with
Figure 3. Expression and activity of components of the renin–
angiotensin system in aortas isolated from rats with or without
adjuvant-induced arthritis (AIA). A, Western blot analysis of angio-
tensin II type 1 receptor (AT1R) in isolated rat aortas (top) and
densitometric quantification of the corresponding bands (bottom).
Densitometric quantification was performed using image analysis
software from the National Institutes of Health. Values are the mean
and SEM of 5 rats per group. GAPDH was included as a loading
control for protein in the Western blots. B, AT1R and angiotensin-
converting enzyme (ACE) mRNA expression in isolated rat aortas.
Real-time polymerase chain reaction analysis was performed as de-
scribed in Materials and Methods. Levels of AT1R and ACE mRNA
were normalized to the level of GAPDH mRNA. C, ACE activity in
isolated aortas (n  6 rats per group). Aortic ACE activity was
measured in a fluorescence assay as described in Materials and
Methods. Values are the mean and SEM of 6 rats per group and are
expressed relative to the control values.   P  0.05 versus normal
control rats.
Figure 4. Reduction of oxidative stress in the aortas of rats with
adjuvant-induced arthritis (AIA) treated with angiotensin II type 1
receptor (AT1R) blockers. A, Superoxide (O2
) production in aortic
tissues of normal control rats and rats with AIA that were left untreated
or were treated with an AT1R blocker: losartan (Los; 3 mg/kg/day) or
irbesartan (Irb; 5 mg/kg/day), administered orally for 21 days after the
onset of arthritis. In situ O2
 generation was evaluated by fluorogenic
oxidation of dihydroethidium (DHE) to ethidium, with imaging by
confocal laser scanning microscopy (magnification  200). Representa-
tive images are shown (top). The mean fluorescence intensity of the aortic
tissues (bottom) was quantified as described in Materials and Methods. B
and C, Activity and expression of NAD(P)H oxidase components in the
aortas of normal control rats and rats with AIA that were left untreated
or were treated with an AT1R blocker: losartan or irbesartan. Homoge-
nates of the isolated aortas were incubated with NADPH, and O2

production was measured according to the lucigenin chemiluminescence
(B). Real-time polymerase chain reaction analysis was performed to
evaluate the mRNA levels of p22phox and gp91phox (C). Values are the
mean and SEM of 6 rats per group.   P  0.05 versus control rats; #
 P  0.05 versus untreated rats with AIA.
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AIA that received high-dose Ang II). Serum triglyceride
levels were significantly lower (P  0.05) in untreated
rats with AIA than in normal rats, as we have previously
reported (17), and the levels were decreased (P  0.05)
by Ang II infusion (mean  SEM 169.3  11.3 pg/ml in
normal rats, 55.8  6.7 in untreated rats with AIA,
123.8  10.7 in rats treated with low-dose Ang II, 38.2 
4.1 in rats with AIA that received low-dose Ang II,
109.3  7.7 in rats treated with high-dose Ang II, and
35.2  8.4 in rats with AIA that received high-dose Ang
II).
We also attempted to measure serum levels of
TNF, which potentially affects endothelial dysfunction
and vascular hypertrophy. However, serum concentra-
tions of this cytokine in untreated rats with AIA or in
Ang II–treated rats with AIA were below the sensitivity
of ELISA used in our study.
Increased expression of AT1R in the aortas of
rats with AIA. To examine the mechanism underlying
the exacerbation of Ang II–induced vascular responses
in rats with AIA, we assessed the expression of AT1R in
their aortas. We found that both protein and mRNA
levels of AT1R in the aortas of rats with AIA were
significantly higher (P  0.05) than those in the aortas of
control rats (Figures 3A and B). We further found that
mRNA levels and enzymatic activity of ACE in the
aortas were significantly higher (P  0.05) in rats with
AIA than in normal rats (Figures 3B and C).
We also found in the present study that infusion
of Ang II increased the mRNA expression levels of
AT1R and ACE. Furthermore, Ang II–induced expres-
sion levels of both AT1R and ACE were significantly
enhanced in rats with AIA as compared with control rats
(results not shown).
Effect of AT1R blockers on enhanced oxidative
stress in the aortas of rats with AIA. To investigate
whether RAS activation is involved with the enhanced
vascular oxidative stress, rats with AIA were treated for
21 days with 1 of 2 different compounds of AT1R
blocker: losartan or irbesartan. Vascular O2
– production
was evaluated by dihydroethidium conversion to
ethidium and was imaged by confocal laser scanning
microscopy (Figure 4A). Both losartan and irbesartan
were found to decrease the levels of O2
– that were
expressed in the tissue.
The physical features of the rats are summarized
in Table 1. Despite the apparent antioxidative effect on
the vasculature, neither losartan nor irbesartan affected
the clinical severity of arthritis during the course of
disease. Administration of losartan to rats with AIA did
not alter blood pressure. Blood pressure in rats with
AIA tended to be decreased following 21 days of
treatment with irbesartan, but the reduction was not
statistically significant (P  0.065). The mean body
weight of rats with AIA was 80% of the weight of normal
control rats and was not significantly affected by treat-
ment with the AT1R blockers.
We next investigated the activity and expression
of NAD(P)H oxidases in rat aortas. Consistent with our
previous findings (16,17), NAD(P)H oxidase–derived
O2
 production and expression of mRNA for NAD(P)H
oxidase components p22phox and gp91phox were signifi-
cantly higher in the aortas of rats with AIA than in the
aortas of normal rats (Figures 4B and C). In the present
study, we found that the activity and expression of
NAD(P)H oxidases in the aorta of rats with AIA were
decreased by treatment with the AT1R blockers (Figures
4B and C).
AT1R blocker–induced improvement in endothe-
lial dysfunction in rats with AIA. We evaluated
endothelium-dependent and endothelium-independent
vasodilatory responses in rats with AIA treated with
each of the AT1R blockers. Consistent with the results of
our previous studies (16,17), the endothelium-









Normal rats 307  11 119  2 0 1.70  0.02
Rats with AIA
Untreated 245  11† 122  2 5.8  0.2 2.03  0.09†
Losartan-treated 224  8† 125  4 5.7  0.3 2.23  0.04†
Irbesartan-treated 212  4† 114  3 5.6  0.2 2.38  0.11†
* Rats with adjuvant-induced arthritis (AIA) were left untreated or were treated orally with losartan at a
dosage of 3 mg/kg/day or with irbesartan at a dosage of 5 mg/kg/day for 21 days after the onset of arthritis.
Body weight, systolic blood pressure (BP), arthritis score, and paw volume were measured 21 days after
the onset of arthritis. The arthritis score and paw volume were assessed as described in Materials and
Methods. Values are mean  SEM of 6 rats per group.
† P  0.05 versus normal rats.
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dependent relaxation of the aortic ring was significantly
depressed in rats with AIA as compared with normal
control rats. We found that in vivo treatment with
losartan or irbesartan mitigated the endothelial dysfunc-
tion in AIA (P  0.05) (Figure 5A). There was no
difference in the endothelium-independent vascular re-
sponses among control rats, rats with AIA, and rats with
AIA treated with AT1R blockers (Figure 5A). We
confirmed that coadministration of L-NAME consider-
ably inhibited the acetylcholine-induced relaxation, sug-
gesting that it is indeed nitric oxide–dependent (Figure
5A).
We further explored whether ex vivo incubation
of aortic rings with AT1R blockers reduces endothelial
dysfunction. Aortic rings isolated from rats with AIA
were incubated for 18 hours in the presence or absence
of losartan or irbesartan, and the endothelium-
dependent and endothelium-independent vascular re-
sponses were determined. We found that ex vivo treat-
ment with each of the AT1R blockers significantly
improved the endothelial dysfunction in AIA aortas
(P  0.05) (Figure 5B).
DISCUSSION
To our knowledge, this is the first study to
evaluate the role of the RAS in vascular damage in an
animal model of autoimmune/inflammatory disease. We
hypothesized that RAS activation is involved in the
development of vascular damage in AIA, and we ob-
tained several pieces of evidence to support this hypothe-
sis. First, Ang II–induced vascular responses were exac-
erbated in rats with AIA. Second, expression of AT1R
was significantly increased in the aortas of these rats.
Third, vascular expression and activity of ACE, a key
enzyme in the formation of Ang II, were enhanced in
AIA. Fourth, AT1R blockers improved endothelial dys-
function and reduced vascular oxidative stress in AIA.
Based on these results, we conclude that local activation
of the RAS in the vasculature plays a critical role in the
increased vascular oxidative stress and endothelial dys-
function in the AIA model.
Morbidity and mortality from cardiovascular dis-
eases are increased in patients with RA (1–5). However,
evidence-based interventional strategies that will pre-
vent the development of cardiovascular events have not
yet been established. In the current study, we demon-
strated that both losartan and irbesartan have potent
vascular protective effects in the AIA animal model of
RA. Our findings provide a scientific rationale for a trial
of RAS inhibitors to reduce cardiovascular mortality in
patients with RA.
A limited number of previous studies have dem-
onstrated that AT1R blockade exerts antiarthritic ef-
fects. In murine collagen-induced arthritis, olmesartan
administered orally at a dosage of 10 mg/kg/day was
shown to suppress arthritis (35). In a rat model of acute
monarthritis, losartan administered subcutaneously on
alternate days at a dose of 15 mg/kg was shown to inhibit
arthritis (36). However, in the present study, neither
Figure 5. Effect of angiotensin II type 1 receptor (AT1R) blockers on
endothelial dysfunction measured ex vivo in rats with adjuvant-induced
arthritis (AIA). A, Analysis of thoracic aortic rings prepared from the
aortas of normal control rats or rats with AIA that were left untreated
or were treated with an AT1R blocker: losartan (Los; 3 mg/kg/day) or
irbesartan (Irb; 5 mg/kg/day), administered orally for 21 days after the
onset of arthritis. Levels of endothelium-dependent vasodilation in-
duced by acetylcholine and endothelium-independent vasodilation
induced by sodium nitroprusside were determined. The effect of
coadministration of NG-nitro-L-arginine methyl ester (L-NAME; a
nitric oxide synthase inhibitor [10–4M]) on acetylcholine-induced va-
sodilation is also shown. B, Analysis of thoracic aortic rings isolated
from rats with AIA that were incubated for 18 hours in the presence or
absence of 10 M losartan or irbesartan. Levels of endothelium-
dependent and endothelium-independent vascular responses were
determined as above. Values are the mean  SEM of 6 rats per group.
  P  0.05 versus untreated rats with AIA.
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AT1R blocker—losartan (3 mg/kg/day) or irbesartan (5
mg/kg/day)—influenced the clinical severity of arthritis
or body weight in rats with AIA. These discrepancies
could be explained by the differences in models, drugs,
and drug doses. In human RA, no controlled study has
demonstrated that AT1R blockers have significant anti-
arthritic effects.
Blood pressure values in rats with AIA were not
significantly reduced by treatment with 3 mg/kg of
losartan or 5 mg/kg of irbesartan, although these doses
are almost equivalent to those currently used therapeu-
tically in humans. This finding is actually consistent with
those of previous studies (37–39) and could be explained
by differences in species. It was shown in hypertensive
rats that losartan administered orally at a dose of 5 or 10
mg/kg did not affect blood pressure, whereas a higher
dose (30 mg/kg) of this drug did reduce blood pressure
(37,38). Irbesartan administered orally to hypertensive
rats at a dose of 3, 10, 30, or 100 mg/kg was shown to
reduce blood pressure in a dose-dependent manner,
although the hypotensive effects induced by lower doses
(3 or 10 mg/kg) of this drug were weak and did not last
for 24 or 48 hours (39). Our results suggest that the
vascular protective effect of AT1R blockers in this model
of arthritis can be independent of antihypertensive ef-
fects and probably occur with the use of lower doses.
The effects of AT1R blockers on improvement in
endothelium-dependent vasodilation may be produced
not only by their AT1R blockade effect, but also by their
inverse agonistic effect against AT1R and their capacity
for scavenging reactive oxygen species. Indeed, we found
in the present study that ex vivo incubation of aortas
from rats with AIA with the AT1R blockers improved
endothelial dysfunction (Figure 5B). Renin and angio-
tensinogen are not present in vitro; thus, Ang II is not
formed in this system. But, AT1R exists abundantly in
the aorta, and its expression level was increased in the
group with AIA. AT1R is a G protein–coupled receptor,
and it can be activated through an Ang II–independent
mechanism. Recent studies have shown that AT1R
blockers have an inverse agonist effect (40). The binding
of AT1R to the AT1R blocker not only blocks the
potential entry of Ang II into its receptor pocket, but it
also induces an inactive conformation of the receptor.
Losartan is reported to have inverse agonism (41). In
addition, irbesartan has also been shown to have this
inverse agonistic effect (Dr. Shin-ichiro Miura, Depart-
ment of Cardiology, Fukuoka University School of Med-
icine, Fukuoka, Japan: personal communication). These
inverse agonistic effects may explain the results observed
in our ex vivo experiments. Moreover, it has been
indicated that AT1R blockers possess unique in vitro
properties as reactive oxygen species scavengers (e.g.,
hydroxyl radical scavenging and inhibition of the Fenton
reaction) (42). This mechanism may also account for
some of the effects of AT1R blockers in our model.
Ang II–induced hypertensive and vascular hyper-
trophic responses are potentiated in AIA. Ang II–
induced endothelial dysfunction is exacerbated in the
presence of inflammatory arthritis. The increased ex-
pression of AT1R in the aortas of rats with AIA may
contribute in part to the exacerbation of Ang II–induced
vascular responses in this model. In rabbits with hyper-
cholesterolemia, enhanced arterial AT1R expression has
been shown to lead to an elevated functional response in
the vascular wall on Ang II stimulation (43). It is likely
that patients with RA have a cluster of traditional and
disease-specific risk factors that may rank them as
individuals at high risk for the development of cardio-
vascular disease. The significant enhancement of Ang
II–induced vascular responses in the AIA arthritis model
reinforces the hypothesis that the coexistence of uncon-
trolled systemic inflammation and RAS activation car-
ries a considerable risk of vasculopathy in patients with
RA.
It has been shown that AT1R expression is en-
hanced by many agonists, such as insulin, low-density
lipoprotein cholesterol, and progesterone (44–46). It
remains to be determined which mediators are involved
in the increased expression of AT1R in the aortas of the
AIA model. Circulating proinflammatory cytokines pos-
sibly influence the vascular expression of AT1R. IL-6 is
of particular interest, since this cytokine has been dem-
onstrated to induce an up-regulation of AT1R gene and
protein expression in rat cultured vascular smooth mus-
cle cells and in mouse vascular tissue (47). Elucidation of
this mechanism could be critically important to the
establishment of strategies that involve neutralization of
proinflammatory cytokines for the reduction of cardio-
vascular risk in RA patients.
In conclusion, our results indicate that the locally
activated RAS is strongly involved in the increased
vascular oxidative stress and endothelial dysfunction in
autoimmune and inflammatory disease models. AT1R
blockers have potent vascular protective effects in the
AIA animal model of RA. We previously found the
beneficial effects of statins on vascular function in the
arthritis model (17). Based on these findings from
animal models, it may be reasonable to suggest that both
RAS blockers and statins are potential treatment op-
tions for the reduction of the risks of cardiovascular
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damage in patients with RA, although further clinical
studies to support this idea are needed.
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